Search Results
You are looking at 1 - 10 of 503 items for
- Abstract: Aging x
- Abstract: Late effects of cancer treatment x
Search for other papers by Izabelle Lövgren in
Google Scholar
PubMed
Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, UK
Search for other papers by Azadeh Abravan in
Google Scholar
PubMed
Search for other papers by Abigail Bryce-Atkinson in
Google Scholar
PubMed
Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, UK
Search for other papers by Marcel van Herk in
Google Scholar
PubMed
Brain tumours make up nearly one-third of paediatric malignancies. Over time, advancements in oncological treatments like radiotherapy have helped reduce normal-tissue toxicity when treating cancers in the brain. However, clinicians are still facing a trade-off between treatment efficacy and potential side effects. The aim of this review is to address the late effects of cranial irradiation on the neuroendocrine system and to identify factors that make patients more vulnerable to radiation-induced endocrine sequelae. Radiation damage to the hypothalamic–pituitary axis, which orchestrates hormone release, can lead to endocrinopathy; up to 48.8% of children who have undergone cranial irradiation develop a hormone deficiency. This may lead to further health complications that can appear up to decades after the last treatment, lowering the patients’ quality of life and increasing long-term costs as lifelong hormone replacement therapy may be required. Growth hormone deficiency is the most common sequelae, followed by either thyroid or gonadotropic hormone deficiency. Adrenocorticotropic hormone deficiency tends to be the least common. Identified factors that increase the risk of late endocrine deficiency include total radiation dose, age at treatment, and time since last treatment. However, as there are various other factors that may potentiate the damage, a universal solution proven to be most effective in sparing the endocrine tissues is yet to be identified. Until then, accounting for the identified risk factors during treatment planning may in some cases help reduce the development of endocrine sequelae in childhood cancer survivors.
Search for other papers by J Gebauer in
Google Scholar
PubMed
Search for other papers by R Skinner in
Google Scholar
PubMed
Search for other papers by R Haupt in
Google Scholar
PubMed
Amsterdam UMC, Emma’s Children’s Hospital, Amsterdam, The Netherlands
Search for other papers by L Kremer in
Google Scholar
PubMed
Search for other papers by H van der Pal in
Google Scholar
PubMed
Search for other papers by G Michel in
Google Scholar
PubMed
Search for other papers by G T Armstrong in
Google Scholar
PubMed
Search for other papers by M M Hudson in
Google Scholar
PubMed
Search for other papers by L Hjorth in
Google Scholar
PubMed
Search for other papers by H Lehnert in
Google Scholar
PubMed
Search for other papers by T Langer in
Google Scholar
PubMed
Many long-term childhood cancer survivors suffer from treatment-related late effects, which may occur in any organ and include a wide spectrum of conditions. Long-term follow-up (LTFU) is recommended to facilitate early diagnosis and to ensure better health outcomes. Due to the heterogeneity of these sequelae, different specialists work together in the diagnosis and treatment of these conditions. Experts from both pediatric and internal medicine are involved in age-appropriate care by providing a transition process. Hence, LTFU of childhood cancer survivors is a prototypic example of multidisciplinary care for patients with complex needs treated in a specialized setting. International collaborations of healthcare professionals and scientists involved in LTFU of childhood cancer survivors, such as the International Guideline Harmonization Group, compile surveillance recommendations that can be clinically adopted all over the world. These global networks of clinicians and researchers make a joint effort to address gaps in knowledge, increase visibility and awareness of cancer survivorship and provide an excellent example of how progress in clinical care and scientific research may be achieved by international and multidisciplinary collaboration.
Search for other papers by W N H Koek in
Google Scholar
PubMed
Search for other papers by N Campos-Obando in
Google Scholar
PubMed
Search for other papers by B C J van der Eerden in
Google Scholar
PubMed
Search for other papers by Y B de Rijke in
Google Scholar
PubMed
Search for other papers by M A Ikram in
Google Scholar
PubMed
Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands
Search for other papers by A G Uitterlinden in
Google Scholar
PubMed
Search for other papers by J P T M van Leeuwen in
Google Scholar
PubMed
Search for other papers by M C Zillikens in
Google Scholar
PubMed
Background
Sex differences in calcium and phosphate have been observed. We aimed to assess a relation with age.
Methods
We used the laboratory values of serum calcium, phosphate and albumin from three different samples ( 2005, 2010 and 2014 years) using the hospital information system of Erasmus MC, Rotterdam. The samples were divided into three age groups: 1–17, 18–44 and ≥45 years. Sex differences in calcium and phosphate were analyzed using ANCOVA, adjusting for age and serum albumin. Furthermore, sex by age interactions were determined and we analyzed differences between age groups stratified by sex.
Results
In all three samples there was a significant sex × age interaction for serum calcium and phosphate, whose levels were significantly higher in women compared to men above 45 years. No sex differences in the younger age groups were found. In men, serum calcium and phosphate levels were highest in the youngest age group compared to age groups of 18–44 and ≥45 years. In women, serum calcium levels were significantly higher in the age group 1–17 and the age group ≥45 years compared to the 18–44 years age group. In women, serum phosphate was different between the three different age groups with highest level in the group 1–17 years and lowest in the group 18–44 years.
Conclusion
There are age- dependent sex differences in serum calcium and phosphate. Furthermore, we found differences in serum calcium and phosphate between different age groups. Underlying mechanisms for these age- and sex- differences are not yet fully elucidated.
Search for other papers by Sandra N Slagter in
Google Scholar
PubMed
Search for other papers by Robert P van Waateringe in
Google Scholar
PubMed
Search for other papers by André P van Beek in
Google Scholar
PubMed
Search for other papers by Melanie M van der Klauw in
Google Scholar
PubMed
Search for other papers by Bruce H R Wolffenbuttel in
Google Scholar
PubMed
Search for other papers by Jana V van Vliet-Ostaptchouk in
Google Scholar
PubMed
Introduction
To evaluate the prevalence of metabolic syndrome (MetS) and its individual components within sex-, body mass index (BMI)- and age combined clusters. In addition, we used the age-adjusted blood pressure thresholds to demonstrate the effect on the prevalence of MetS and elevated blood pressure.
Subjects and methods
Cross-sectional data from 74,531 Western European participants, aged 18–79 years, were used from the Dutch Lifelines Cohort Study. MetS was defined according to the revised NCEP-ATPIII. Age-adjusted blood pressure thresholds were defined as recommended by the eight reports of the Joint National Committee (≥140/90 mmHg for those aged <60 years, and ≥150/90 mmHg for those aged ≥60 years).
Results
19.2% men and 12.1% women had MetS. MetS prevalence increased with BMI and age. Independent of BMI, abdominal obesity dominated MetS prevalence especially in women, while elevated blood pressure was already highly prevalent among young men. Applying age-adjusted blood pressure thresholds resulted in a 0.2–11.9% prevalence drop in MetS and 6.0–36.3% prevalence drop in elevated blood pressure, within the combined sex, BMI and age clusters.
Conclusions
We observed a gender disparity with age and BMI for the prevalence of MetS and, especially, abdominal obesity and elevated blood pressure. The strict threshold level for elevated blood pressure in the revised NCEP-ATPIII, results in an overestimation of MetS prevalence.
Tropical Institute of Reproductive Medicine, Cuiabá, Mato Grosso, Brazil
Search for other papers by Sebastião Freitas de Medeiros in
Google Scholar
PubMed
Search for other papers by Márcia Marly Winck Yamamoto in
Google Scholar
PubMed
Search for other papers by Matheus Antônio Souto de Medeiros in
Google Scholar
PubMed
Search for other papers by Bruna Barcelo Barbosa in
Google Scholar
PubMed
Search for other papers by José Maria Soares Junior in
Google Scholar
PubMed
Search for other papers by Edmund Chada Baracat in
Google Scholar
PubMed
Objective
To verify whether aging can modify the clinical and biochemical characteristics of women with polycystic ovary syndrome (PCOS).
Material and methods
This observational cross-sectional study was conducted at the reproductive endocrinology clinics of Julio Muller University Hospital and Tropical Institute of Reproductive Medicine in Cuiabá, MT, Brazil, between 2003 and 2017. Both, 796 PCOS and 444 non-PCOS normal cycling women underwent the same examination. PCOS was diagnosed using the Rotterdam criteria as recommended for adolescent and adult subjects. Anthropometric, metabolic, and endocrinological modifications with aging were initially examined in the two groups: control and PCOS. Further analyses were performed after a 5-year age stratification of data throughout the reproductive period. All participants signed a consent form approved by the local ethical committee.
Results
Biomarkers of adiposity were more remarkable in African descendant PCOS women. Body weight, waist/hip ratio, fat mass, and BMI were higher in PCOS women and tended to increase at all 5 age-strata, between ≤19 and 35 years of age. Serum androgen levels decreased with aging, markedly in PCOS subjects (P < 0.01 for all age-strata comparisons), but remained elevated when compared with the levels found in controls. Carbohydrate markers, triglycerides, and total cholesterol tended to increase over time in PCOS (P < 0.01 for all age-strata comparisons). Total cholesterol also tended to increase with age in non-PCOS women (P = 0.041).
Conclusion
The present study has shown that the advancing age influences many features of PCOS women. Biochemical hyperandrogenism, the core criterion recommended in the current systems to define the syndrome, showed statistically significant tendencies to decrease with aging progression but did not normalize. The use of age-adjusted features for the diagnosis of PCOS are recommended.
Shandong Provincial Key Laboratory of Oral Tissue Regeneration, Jinan, People’s Republic of China
Search for other papers by Tingting Jia in
Google Scholar
PubMed
Shandong Provincial Key Laboratory of Oral Tissue Regeneration, Jinan, People’s Republic of China
Search for other papers by Ya-nan Wang in
Google Scholar
PubMed
Shandong Provincial Key Laboratory of Oral Tissue Regeneration, Jinan, People’s Republic of China
Search for other papers by Dongjiao Zhang in
Google Scholar
PubMed
Shandong Provincial Key Laboratory of Oral Tissue Regeneration, Jinan, People’s Republic of China
Search for other papers by Xin Xu in
Google Scholar
PubMed
Diabetes-induced advanced glycation end products (AGEs) overproduction would result in compromised osseointegration of titanium implant and high rate of implantation failure. 1α,25-dihydroxyvitamin D3 (1,25VD3) plays a vital role in osteogenesis, whereas its effects on the osseointegration and the underlying mechanism are unclear. The purpose of this study was to investigate that 1,25VD3 might promote the defensive ability of osseointegration through suppressing AGEs/RAGE in type 2 diabetes mellitus. In animal study, streptozotocin-induced diabetic rats accepted implant surgery, with or without 1,25VD3 intervention for 12 weeks. After killing, the serum AGEs level, bone microarchitecture and biomechanical index of rats were measured systematically. In vitro study, osteoblasts differentiation capacity was analyzed by alizarin red staining, alkaline phosphatase assay and Western blotting, after treatment with BSA, AGEs, AGEs with RAGE inhibitor and AGEs with 1,25VD3. And the expression of RAGE protein was detected to explore the mechanism. Results showed that 1,25VD3 could reverse the impaired osseointegration and mechanical strength, which possibly resulted from the increased AGEs. Moreover, 1,25VD3 could ameliorate AGEs-induced damage of cell osteogenic differentiation, as well as downregulating the RAGE expression. These data may provide a theoretical basis that 1,25VD3 could work as an adjuvant treatment against poor osseointegration in patients with type 2 diabetes mellitus.
Department of Urology, Foundation IRCCS Ca’ Granda – Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
Search for other papers by Luca Boeri in
Google Scholar
PubMed
Search for other papers by Paolo Capogrosso in
Google Scholar
PubMed
University Vita-Salute San Raffaele, Milan, Italy
Search for other papers by Walter Cazzaniga in
Google Scholar
PubMed
University Vita-Salute San Raffaele, Milan, Italy
Search for other papers by Edoardo Pozzi in
Google Scholar
PubMed
University Vita-Salute San Raffaele, Milan, Italy
Search for other papers by Luigi Candela in
Google Scholar
PubMed
University Vita-Salute San Raffaele, Milan, Italy
Search for other papers by Federico Belladelli in
Google Scholar
PubMed
University Vita-Salute San Raffaele, Milan, Italy
Search for other papers by Davide Oreggia in
Google Scholar
PubMed
Search for other papers by Eugenio Ventimiglia in
Google Scholar
PubMed
University Vita-Salute San Raffaele, Milan, Italy
Search for other papers by Nicolò Schifano in
Google Scholar
PubMed
University Vita-Salute San Raffaele, Milan, Italy
Search for other papers by Giuseppe Fallara in
Google Scholar
PubMed
Search for other papers by Marina Pontillo in
Google Scholar
PubMed
Search for other papers by Costantino Abbate in
Google Scholar
PubMed
Search for other papers by Emanuele Montanari in
Google Scholar
PubMed
University Vita-Salute San Raffaele, Milan, Italy
Search for other papers by Francesco Montorsi in
Google Scholar
PubMed
University Vita-Salute San Raffaele, Milan, Italy
Search for other papers by Andrea Salonia in
Google Scholar
PubMed
Objective:
We aimed to test the association between age, BMI and sex-hormone–binding globulin (SHBG) in a homogenous cohort of white-European men presenting for primary couple’s infertility.
Design:
Retrospective study.
Methods:
Data from 1547 infertile men were analysed. Health-significant comorbidities were scored with the Charlson comorbidity index (CCI). Fasting serum hormones were measured in every patient. Age was considered according to quartile groups (<33, 33-41, >41 years) and BMI as normal weight (18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2) and obesity (>30 kg/m2). Descriptive statistics and linear regression analysis tested the associations between age, BMI and SHBG.
Results:
Median SHBG levels increased across quartiles of age and decreased along with BMI increases (all P < 0.001). For each year increase in age, SHBG increased 0.32 nmol/L; conversely, for each unit increase in BMI, SHBG decreased by 1.1 nmol/L (all P < 0.001). SHBG levels decline with increasing BMI was greater than SHBG progressive increase with age. Overall, BMI explained 3.0 times more of the variability in SHBG than did ageing. At multivariate linear model, age and BMI were the most significant factors influencing SHBG concentration (all P < 0.001), after accounting for CCI, albumin levels and smoking status.
Conclusions:
We found a wide distribution of SHBG concentrations across age and BMI values in primary infertile men. The association between BMI and lowered SHBG levels seems to be greater than the association of ageing with increased SHBG.
Search for other papers by Fang Lv in
Google Scholar
PubMed
Search for other papers by Xiaoling Cai in
Google Scholar
PubMed
Search for other papers by Chu Lin in
Google Scholar
PubMed
Search for other papers by Tianpei Hong in
Google Scholar
PubMed
Search for other papers by Xiaomei Zhang in
Google Scholar
PubMed
Search for other papers by Zhufeng Wang in
Google Scholar
PubMed
Search for other papers by Huifang Xing in
Google Scholar
PubMed
Search for other papers by Guizhi Zong in
Google Scholar
PubMed
Search for other papers by Juming Lu in
Google Scholar
PubMed
Search for other papers by Xiaohui Guo in
Google Scholar
PubMed
Search for other papers by Jing Wu in
Google Scholar
PubMed
Search for other papers by Leili Gao in
Google Scholar
PubMed
Search for other papers by Xianghai Zhou in
Google Scholar
PubMed
Search for other papers by Xueyao Han in
Google Scholar
PubMed
Search for other papers by Linong Ji in
Google Scholar
PubMed
Aims
To estimate the sex differences in the prevalence of overweight and obesity aged 20–89 in Chinese patients with type 2 diabetes (T2D).
Methods
811,264 patients with T2D from six hospital-based, cross-sectional studies, and 46,053 subjects from the general population were included in our analysis. Prevalence of underweight, overweight, obesity were calculated in each sex.
Results
In patients with T2D, the standardized prevalence of underweight (BMI <18.5 kg/m2), overweight (24 kg/m2 ≤ BMI < 28 kg/m2), and general obesity (BMI ≥28 kg/m2) were 2.2%, 43.2%, and 11.6%, respectively. Similar trend patterns of the prevalence of underweight and overweight were observed in general and T2D population, in males and females with T2D (all P for trend <0.01). In patients with T2D, patients at a younger age and older age were more likely to be underweight. The prevalence of overweight increased first, then stabilized or decreased with age. However, different trend patterns of the prevalence of obesity in males and females were found. In males, the prevalence of obesity decreased first, and then stabilized after 60 years of age. In females, the prevalence of obesity decreased first, then increased after 50 years of age. In the general population, the prevalence of obesity increased with age in females, while, the trend of prevalence of obesity with age in males was not obvious.
Conclusion
Different trends in the prevalence of obesity with age in different sex were found in Chinese patients with T2D.
Search for other papers by Andrea Mazurat in
Google Scholar
PubMed
Search for other papers by Andrea Torroni in
Google Scholar
PubMed
Search for other papers by Jane Hendrickson-Rebizant in
Google Scholar
PubMed
Search for other papers by Harbinder Benning in
Google Scholar
PubMed
Search for other papers by Richard W Nason in
Google Scholar
PubMed
Search for other papers by K Alok Pathak in
Google Scholar
PubMed
Well-differentiated thyroid carcinoma (WDTC) represents a group of thyroid cancers with excellent prognosis. Age, a well-recognized risk factor for WDTC, has been consistently included in various prognostic scoring systems. An age threshold of 45 years is currently used by the American Joint Cancer Committee-TNM staging system for the risk stratification of patients. This study analyzes the relationship between the patients' age at diagnosis and thyroid cancer-specific survival in a population-based thyroid cancer cohort of 2115 consecutive patients with WDTC, diagnosed during 1970–2010, and evaluates the appropriateness of the currently used age threshold. Oncological outcomes of patients in terms of disease-specific survival (DSS) and disease-free survival (DFS) were calculated by the Kaplan–Meier method, while multivariable analysis was done by the Cox proportional hazard model and proportional hazards regression for sub-distribution of competing risks to assess the independent influence of various prognostic factors. The mean age of the patients was 47.3 years, 76.6% were female and 83.3% had papillary carcinoma. The median follow-up of the cohort was 122.4 months. The DSS and DFS were 95.4 and 92.8% at 10 years and 90.1 and 87.6% at 20 years, respectively. Multivariable analyses confirmed patient's age to be an independent risk factor adversely affecting the DSS but not the DFS. Distant metastasis, incomplete surgical resection, T3/T4 stages, Hürthle cell histology, and male gender were other independent prognostic determinants. The DSS was not independently influenced by age until the age of 55 years. An age threshold of 55 years is better than that of 45 years for risk stratification.
Search for other papers by Ferdinand Roelfsema in
Google Scholar
PubMed
Search for other papers by Diana van Heemst in
Google Scholar
PubMed
Search for other papers by Ali Iranmanesh in
Google Scholar
PubMed
Search for other papers by Paul Takahashi in
Google Scholar
PubMed
Search for other papers by Rebecca Yang in
Google Scholar
PubMed
Search for other papers by Johannes D Veldhuis in
Google Scholar
PubMed
Context
Studies on 24-h cortisol secretion are rare. The impact of sex, age and adiposity on cortisol levels, often restricted to one or a few samples, are well recognized, but conflicting.
Objective
To investigate cortisol dynamics in 143 healthy men and women, spanning 7 decades and with a 2-fold body mass index (BMI) range with different analytic tools.
Setting
Clinical Research Unit.
Design
Cortisol concentrations in 10-min samples collected for 24 h. Outcomes were mean levels, deconvolution parameters, approximate entropy (ApEn, regularity statistic) and 24-h rhythms.
Results
Total 24-h cortisol secretion rates estimated by deconvolution analysis were sex, age and BMI independent. Mean 24-h cortisol concentrations were lower in premenopausal women than those in men of comparable age (176 ± 8.2 vs 217 ± 9.4 nmol/L, P = 0.02), but not in subjects older than 50 years. This was due to lower daytime levels in women, albeit similar in the quiescent overnight period. Aging increased mean cortisol by 10 nmol/L per decade during the quiescent secretory phase and advanced the acrophase of the diurnal rhythm by 24 min/decade. However, total 24-h cortisol secretion rates estimated by deconvolution analysis were sex, age and BMI independent. ApEn of 24-h profiles was higher (more random) in premenopausal women than those in men (1.048 ± 0.025 vs 0.933 ± 0.023, P = 0.001), but not in subjects older than 50 years. ApEn peaked during the daytime.
Conclusion
Sex and age jointly determine the 24-h cortisol secretory profile. Sex effects are largely restricted to age <50 years, whereas age effects elevate concentrations in the late evening and early night and advance the timing of the peak diurnal rhythm.
